Tagged Articles

diabetic ketoacidosis 11 articles

Docs paid more to promote Invokana than any other diabetes med

Doctors were paid a total of $20.9 million in 2015 to promote Invokana – millions more than any other type 2 diabetes medication, according to ProPublica’s updated Dollars for Docs database. The money covered so-called “general payments” involving fees, meals, travel, gifts and royalties to health care providers for promotional speeches or consulting related to Invokana. The payments do not include research. Diabetes is a growing epidemic in the United States. About 29.1 million Americans have been diagnosed with the chronic condition. People with diabetes must follow a lifelong strict diet and monitor their blood sugar daily. Many rely on ... Read More

Number of lawsuits in Invokana MDL expected to grow

Fifty-five lawsuits alleging the type 2 diabetes drug Invokana caused health risks were consolidated in New Jersey federal court Dec. 8 by the Judicial Panel for Multidistrict Litigation, and that number is expected to grow. The panel says it expects an additional 44 cases to be filed in the U.S. District court for the District of New Jersey, transferred from districts in Minnesota, Illinois, Kentucky, Missouri, Virginia and West Virginia. The lawsuits target Invokana makers Johnson & Johnson subsidiary Janssen Pharmaceuticals and Mitsubishi Tanabe Pharmaceuticals, claiming the drug companies failed to warn doctors or patients of the risks associated with ... Read More

Plaintiffs suing Invokana makers seek to consolidate litigation

There is more movement in the growing litigation involving injuries allegedly caused by the type 2 diabetes drug Invokana. Plaintiffs with claims pending in the Philadelphia Court of Common Pleas are seeking to consolidate their claims into a mass tort program. Currently, 87 cases are pending in Philadelphia. They are reportedly virtually identical. Consolidating them would cut down on legal costs and increase efficiency. Meanwhile, a motion was filed with the U.S. Judicial Panel on Multidistrict Litigation (MDL) Requesting that federal claims be consolidated into the Trenton Division of the U.S. District Court of the District of New Jersey. At least ... Read More

Diabetics taking an SGLT2 inhibitor should watch for ketoacidosis signs

Diabetic ketoacidosis, or DKA, is a serious condition that can lead to diabetic coma and even death, warns the American Diabetes Association. Ketoacidosis occurs when the cells don’t get the glucose they need for energy, causing the body to burn fat for energy, which produces ketones. Ketones are chemicals that the body creates when it breaks down fat to use for energy. The body reacts this way when it does not have enough insulin to use glucose, the body’s natural source of energy. When ketones build up in the blood, they make it more acidic. Symptoms of ketoacidosis usually come ... Read More

More research needed to investigate side effects with newer class of type 2 diabetes drugs

More research should be conducted on a newer class of type 2 diabetes drugs to better understand side effects such as diabetic ketoacidosis and bone fractures, and to determine if the risks are drug-specific or spread among all treatments in the class, said Rodica Busui, MD, PhD, with the University of Michigan Health System. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new type of type 2 diabetes treatment that lower blood sugar by blocking the reabsorption of glucose in the kidneys and increase the excretion of glucose through the urine. Brand names include Invokana, Invokamet, Farxiga, Xigduo and Jardiance. The first ... Read More

Invokana increases the risk of ketoacidosis in type 1 diabetics on insulin

Cases of ketoacidosis were reported in type 1 diabetic patients taking insulin in combination with the diabetes medication Invokana as early as 18 weeks after starting the drug, according to researchers with the American Diabetes Association. Invokana is approved to treat patients with type 2 diabetes, but the drug has been tested in patients with type 1 diabetes. Studies have already linked Invokana (known chemically as canagliflozin) and other type 2 diabetes drugs in the same class known as sodium glucose cotransporter 2 (SGLT2) inhibitors, with an increased risk of ketoacidosis. The new study aimed to evaluate whether the incidence ... Read More

New Invokana side effects lawsuits filed in NJ federal court

Three lawsuits filed by patients alleging they suffered kidney damage and heart disease from Johnson & Johnson’s type 2 diabetes drug Invokana have been filed in federal court in New Jersey. The lawsuits name Johnson & Johnson, its subsidiary Janssen Pharmaceuticals, and Mitsubishi Tanabe Pharma Corp., the company that developed Invokana, as defendants. One of the lawsuits was filed on behalf of South Carolina resident Cornelius Benjamin. It claims Benjamin began taking Invokana to treat his diabetes in April 2013. He suffered a stroke and kidney damage, and died two months after beginning treatment with Invokana. Another lawsuit, filed by ... Read More

Doctors should educate patients taking Invokana about ketoacidosis symptoms

Less than a year after the U.S. Food and Drug Administration (FDA) warned of ketoacidosis risk in patients taking a class of type 2 diabetes drugs known as SGLT2 inhibitors, the European Commission issued the same warning. Now drug authorities in both countries are urging health care providers to be vigilant and educate patients about the signs and symptoms of the serious condition. Both groups say SGLT2 inhibitors, which include Invokana and Invokamet, are effective at lowering blood sugar levels in some patients, but there is a risk for developing ketoacidosis. The condition occurs when too many ketones build up ... Read More

European doctors advised to consider ketoacidosis in patients taking Invokana

European drug regulators are advising physicians who treat patients taking a newer type 2 diabetes treatment known as SGLT2 inhibitors to consider the possibility of diabetic ketoacidosis even if their blood sugar levels are not high. The recommendation comes after a safety review by an advisory panel to the European Medicines Agency (EMA) during which the committee reviewed cases of life threatening diabetic ketoacidosis in patients with type 2 diabetes who had not presented with the typical symptoms of the disease. Diabetic ketoacidosis most often is seen in type 1 diabetics, and is generally accompanied by high blood sugar levels ... Read More

Kardashian star diagnosed with ketoacidosis

Television personality and businessman Rob Kardashian, best known for his role on Keeping Up with the Kardashians and its spin-offs, as well as a stint on Dancing with the Stars, was diagnosed with life threatening diabetic ketoacidosis, according to TMZ. Ketoacidosis is a serious condition that affects diabetics. Kardashian, 28, said he didn’t know he had diabetes. The condition occurs when too much acid builds up in the blood. Patients usually experience symptoms such as nausea, vomiting, abdominal pain, tiredness and trouble breathing. If left untreated, it can lead to diabetic coma and death. Ketoacidosis is most often seen in ... Read More